- New insights into BriaDX™, BriaCell’s simple patient HLA-type identification test, will be presented
at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium held in in San Francisco, California, February 28-March 2,
2019.
- Dr. Charles L. Wiseman will be a keynote speaker at Euro Breast Cancer Summit held in Paris, France,
March 20-21, 2019.
- Scientific findings supporting the development of Bria-OTS™, personalized off-the-shelf immunotherapy,
will be presented at American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia, March 29-April 3,
2019.
- Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) combination study is ongoing, with data to
be press released late 1Q-2019 on a date to be communicated.
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.
(TSX-V:BCT) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology
company with a proprietary targeted immunotherapy technology, today announces it has been selected to present a poster at the 2019
ASCO-SITC Clinical Immuno-Oncology Symposium, held February 28–March 2, 2019, in San Francisco, California. The poster will
highlight findings related to the mechanism of action of the Company’s lead candidate, Bria-IMT™, to BriaDX™, the companion
diagnostic test aimed at helping identify those patients most likely to benefit from Bria-IMT™, and to Bria-OTS™, BriaCell’s
off-the-shelf personalized immunotherapy. Additionally, Dr. Charles L. Wiseman, BriaCell’s founder and director, will be a keynote
speaker at the 10th Euro Breast Cancer Summit, being held in Paris, France, March 20-21, 2019. Furthermore, BriaCell has
also been accepted to present a poster at the American Association for Cancer Research (AACR) Annual Meeting being held March
29-April 3, 2019, at Georgia World Congress Center, Atlanta, Georgia. The poster will summarize molecular and clinical findings
supporting the advancement of the Bria-OTS™ program.
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
San Francisco, California
February 28–March 2, 2019
BriaCell will highlight important clinical and molecular findings of its completed, 23-subject Phase I/IIa trial
of Bria-IMT™ in patients with advanced breast cancer, including significant tumor regression in certain patients who matched
Bria-IMT™ at HLA types. Additionally, an analysis of immunologic factors will be presented, including delayed-type hypersensitivity
and antibody responses suggesting heightened immune activity in patients treated with Bria-IMT™. HLA-matching subjects had an
improved response rate (i.e., tumor reduction), and HLA matching is currently being evaluated as a predictor of the tumor response
in the ongoing combination study of Bria-IMT™ with KEYTRUDA® [manufactured by Merck & Co., Inc. (NYSE: MRK)], listed in
ClinicalTrials.gov as NCT03328026. These data support the Company’s Bria-OTS™ program.
The details of the poster are as follows:
Abstract Submission ID: 245533
Abstract Number: 6
Title: Targeted tumor-derived cellular immunotherapy in advanced breast cancer patients induces initial immune
responses and tumor regression.
Session Information: Poster Session B
Date: Friday, March 1, 2019,
Time: 11:30 a.m.–1:00 p.m.; 5:30 p.m. – 6:30 p.m. PT
Location: Golden Gate Hall, B2 Level
Poster Board Number: B4
Following the presentation, a copy of the poster will be posted on http://briacell.com/investor-relations/presentations/.
10th Euro Breast Cancer Summit
Paris, France
March 20–21, 2019
Dr. Charles L. Wiseman will be a keynoter speaker at the 10th Euro Breast Cancer Summit, being held in Paris,
France, March 20-21, 2019. This year’s theme will be “Rediscovering Novel Approaches towards Cure for Breast Cancer and Women’s
Health”.
AACR Annual Meeting 2019
Atlanta, Georgia
March 29–April 3, 2019
BriaCell will summarize efficacy and safety data of its lead candidate, Bria-IMT™, as obtained in several
clinical trials. Additionally, insights into Bria-IMT™’s mechanism of action will be provided, which are, in essence, molecular and
clinical findings supporting the development of Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy, program. Bria-OTS™
consists of a set of cell lines under development that are similar to Bria-IMT™ but engineered to produce different human leukocyte
antigen (HLA) antigens to match individual patients. BriaCell anticipates an increased response rate (i.e., tumor reduction) with
HLA-matched Bria-OTS™ cell lines compared to unmatched Bria-IMT™ in advanced breast cancer patients. Bria-OTS™ is currently under
development, with plans to enter the clinic later in 2019.
The details of the poster are as follows:
Abstract Control Number: 3662
Title: Development of a personalized off-the-shelf whole-cell immunotherapy for breast cancer
Session Category: Immunology
Session Title: Immunomodulators and Response to Therapy
Date: Wednesday, April 3, 2019
Time: 8:00 a.m.–12:00 p.m. ET
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 24
Poster Board Number: 21
Permanent Abstract Number: 4998
Following the presentation, a copy of the poster will be posted on http://briacell.com/investor-relations/presentations/.
“An estimated 42,000 women will die of breast cancer in 2019 in the U.S. alone, indicating a substantial unmet
medical need for a large patient population whose tumors had become resistant to chemotherapy or other therapeutic regimens.
Currently, there are no effective treatment options for these patients, leaving them with a very poor prognosis and a grim survival
outlook,” stated Dr. Bill Williams, president and CEO of BriaCell. “We are excited to share our findings with the scientific and
medical community at ASCO-SITC Clinical Immuno-Oncology Symposium and the AACR meeting. We believe that our unique approach is
promising and supports personalizing our immunotherapy to match individual patients. HLA typing may serve as a companion diagnostic
test, BriaDX™, to determine the best match for Bria-IMT™ and for Bria-OTS™, our off-the-shelf personalized immunotherapy, which is
under development for breast cancer patients. Bria-OTS™ has the potential to stimulate the immune system in a manner tailored to
the patient without the complexities associated with other personalized therapies, to bring hope to advanced breast cancer patients
with few effective treatment options. Further studies are merited and in progress, especially for our ongoing combination study of
Bria-IMT™ with KEYTRUDA®.”
Separately, the Company has posted a revamped investor presentation along with more detailed investor and
scientific presentations on BriaCell’s website: http://briacell.com/investor-relations/presentations/.
About ASCO-SITC Clinical Immuno-Oncology Symposium
Designed for clinicians, scientists and all other members of the cancer care and research community,
ASCO-SITC Clinical Immuno-Oncology Symposium is a three-day meeting dedicated to clinical and translational
research and advancements in immuno-oncology and the implications for clinical use and patient care. This
meeting focuses on clinical education in immuno-oncology where all aspects of care are fundamentally different from
traditional therapies.
For more information on ASCO-SITC Clinical Immuno-Oncology Symposium, please visit: https://immunosym.org.
About Euro Breast Cancer Summit
In its 10th year, the Euro Breast Cancer Summit gathers cancer biologists, oncologists, pathologists
and other medical professionals to discuss the latest innovations in the field of breast cancer.
This year’s theme will be “Rediscovering Novel Approaches towards Cure for Breast Cancer and Women’s
Health”.
For more information on Euro Breast Cancer Summit, please visit: https://eurobreastcancer.cancersummit.org/organizing-committee.php.
About AACR
Founded in 1907 in Washington, D.C., May 7, 1907, by a group of 11 physicians and scientists intended “to
further the investigation and spread the knowledge of cancer”, to prevent and cure cancer using research, education, communication,
collaboration, funding, and advocacy have been the mission of AACR. With its programs and services, AACR advances research in
cancer and related biomedical science by facilitating exchange of knowledge and innovations among scientists and clinicians
dedicated to the fight against cancer, providing education and training in oncology treatment and advancing cancer etiology,
prevention, early detection, diagnosis and treatment worldwide.
For more information on AACR, please visit: https://www.aacr.org.
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the
management of cancer.
BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, in a combination
study with pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.). The combination study is listed in
ClinicalTrials.gov as NCT03328026.
BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer.
Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please visit: http://www.BriaCell.com.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains "forward-looking information" within
the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks are more fully described in the Company's public filings
available at www.sedar.com.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics Corp.:
Farrah Dean
Manager, Corporate Development
Email: farrah@BriaCell.com
Phone: 1-888-485-6340
